» Articles » PMID: 36798849

The COVID-19 Wave Was Already Here: High Seroprevalence of SARS-CoV-2 Antibodies Among Staff and Students in a Cameroon University

Abstract

Background: Seroprevalence studies, to estimate the proportion of people that has been infected by SARS-CoV-2 are importance in African countries, where incidence is among the lowest in the world.

Objective: This study aimed at evaluating the exposure to SARS-CoV-2 within a university setting of Cameroon.

Methods: A cross-sectional study performed in December 2020 - December 2021, among students and staffs of the Evangelical University of Cameroon. COVID-19 antigen rapid detection test (RDT) was performed using Standard Q Biosensor, and one year after SARS-CoV-2 antibody-test was performed within the same population using RDT and chemiluminescence immunoassay (CLIA).

Results: 106 participants were enrolled (80% students), female sex was the most represented. Positivity to SARS-CoV-2 was 0.0% based on antigen RDTs. The seroprevalence of SARSCoV- 2 antibodies was estimated at 73.6% (95% CI. 64.5-81.0) for IgG and 1.9% (95% CI. 0.2-6.8) for IgM/IgG with RDTs, and 91.9% (95% CI. 84.7-96.4) for anti-nucleocapsid with CLIA. 95.3% (101) reported having developed at least one of the known COVID-19 symptoms (cough and headache being the most common). 90.3% (28) of people who experienced at least one of these symptoms developed IgG antibodies. 40.6% (43) of participants took natural herbs, whereas 55.7% (59) took conventional drugs. The most used herb was , while the most used drugs were antibiotics.

Conclusion: In this Cameroonian University community, SARS-CoV-2 seroprevalence is high, with a greater detection using advanced serological assays. This indicates a wide viral exposure, and the need to adequate control measures especially for those experiencing any related COVID-19 symptoms.

Citing Articles

Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Bamako, Mali: A Population-Based Cross-Sectional Study in September 2022.

Traore B, Guindo M, Konate D, Kane F, Incandela N, Traore A Influenza Other Respir Viruses. 2024; 18(7):e13343.

PMID: 39044355 PMC: 11300109. DOI: 10.1111/irv.13343.


Serological surveillance reveals a high exposure to SARS-CoV-2 and altered immune response among COVID-19 unvaccinated Cameroonian individuals.

Moguem Soubgui A, Ndeme Mboussi W, Foko L, Embolo Enyegue E, Koanga Mogtomo M PLOS Glob Public Health. 2024; 4(2):e0002380.

PMID: 38346064 PMC: 10861046. DOI: 10.1371/journal.pgph.0002380.


Seroprevalence of SARS-CoV-2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon.

Essomba R, Bayibeki A, Lissom A, Ateba P, Seni N, Fouda C Influenza Other Respir Viruses. 2023; 17(11):e13222.

PMID: 37964992 PMC: 10640965. DOI: 10.1111/irv.13222.

References
1.
Jacobs J, Kuhne V, Lunguya O, Affolabi D, Hardy L, Vandenberg O . Implementing COVID-19 (SARS-CoV-2) Rapid Diagnostic Tests in Sub-Saharan Africa: A Review. Front Med (Lausanne). 2020; 7:557797. PMC: 7662157. DOI: 10.3389/fmed.2020.557797. View

2.
Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi J . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9. PMC: 7723407. DOI: 10.7554/eLife.61312. View

3.
Qiu M, Shi Y, Guo Z, Chen Z, He R, Chen R . Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 2005; 7(5-6):882-9. PMC: 7110836. DOI: 10.1016/j.micinf.2005.02.006. View

4.
Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26(6):845-848. DOI: 10.1038/s41591-020-0897-1. View

5.
Hantz S . [Biological diagnosis of Sars-CoV-2 infection: strategies and interpretation of results]. Rev Francoph Lab. 2020; 2020(526):48-56. PMC: 7604167. DOI: 10.1016/S1773-035X(20)30313-0. View